ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator

ANORO™ ELLIPTA™, a combination anticholinergic and long-acting beta2-adrenergic agonist (LABA), indicated for long-term, once-daily, treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, has received the U.S. Food and Drug Administration (FDA) approval.

It is the first combination product approved in the U.S. that delivers two once-daily bronchodilators in a single inhaler. This approval is a significant achievement for GlaxoSmithKline and Theravance, Inc.

It is anticipated that it will come to market in the US during the first quarter of 2014

One Response to “ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator”

  1. gerald shaffer says:

    how much will anoro ellipta cost?

Leave a Reply